Eli Lilly and (NYSE:LLY) had its target price decreased by analysts at Barclays from $232.00 to $227.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 22.10% from the stock’s previous close.
A number of other research analysts have also issued reports on LLY. Truist boosted their target price on Eli Lilly and from $200.00 to $215.00 in a report on Monday, February 1st. Morgan Stanley dropped their target price on Eli Lilly and from $217.00 to $207.00 and set an “overweight” rating for the company in a research note on Tuesday. Mizuho lowered their price objective on shares of Eli Lilly and from $228.00 to $216.00 and set a “buy” rating for the company in a research note on Tuesday. Cowen increased their price objective on shares of Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a research report on Friday, February 12th. Finally, Bank of America lifted their price objective on shares of Eli Lilly and from $195.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, January 22nd. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $200.75.
LLY stock opened at $185.92 on Tuesday. The company has a market cap of $178.30 billion, a price-to-earnings ratio of 30.38, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37. The company has a fifty day moving average price of $185.84 and a 200 day moving average price of $176.06. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. Eli Lilly and has a 12 month low of $129.21 and a 12 month high of $218.00.
In related news, Director Jackson P. Tai purchased 1,366 shares of Eli Lilly and stock in a transaction dated Friday, April 30th. The stock was bought at an average price of $182.84 per share, for a total transaction of $249,759.44. Following the completion of the acquisition, the director now directly owns 60,649 shares of the company’s stock, valued at $11,089,063.16. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 125,284 shares of the stock in a transaction on Monday, March 8th. The stock was sold at an average price of $209.69, for a total transaction of $26,270,801.96. Following the sale, the insider now directly owns 110,422,933 shares of the company’s stock, valued at approximately $23,154,584,820.77. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ieq Capital LLC acquired a new position in shares of Eli Lilly and during the first quarter worth about $1,923,000. Valmark Advisers Inc. increased its position in shares of Eli Lilly and by 13.2% in the first quarter. Valmark Advisers Inc. now owns 3,560 shares of the company’s stock valued at $665,000 after acquiring an additional 416 shares during the last quarter. Savant Capital LLC raised its holdings in Eli Lilly and by 1.0% during the first quarter. Savant Capital LLC now owns 12,214 shares of the company’s stock worth $2,282,000 after acquiring an additional 119 shares in the last quarter. Pillar Pacific Capital Management LLC boosted its position in Eli Lilly and by 2.6% during the first quarter. Pillar Pacific Capital Management LLC now owns 3,897 shares of the company’s stock valued at $728,000 after purchasing an additional 97 shares during the last quarter. Finally, Alaethes Wealth LLC acquired a new position in shares of Eli Lilly and during the 1st quarter worth approximately $831,000. 75.59% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Featured Article: What is a Stop Order?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.